Background: Different modified sequential therapies have been proposed for Helicobacter pylori eradication. However, the efficacy of these regimens is controversial. Methods: We performed a systematic review of the literature and pooled-data analysis to assess: (a) the efficacy of different modified sequential therapies for H. pylori eradication, (b) the eradication rates achieved by these regimens as compared to either standard triple therapies or standard sequential regimen when available. Results: Overall 21 trials met inclusion criteria. The most used modified sequential therapy was the seven plus seven tetracycline-based regimen which achieved an overall 73.3% eradication rate (6 trials). Such therapy was more effective than the 14-day triple therapy (77.2% vs. 63.6%; 3 trials). The most used five plus five levofloxacin-based sequential therapy achieved a 95.8% and 90% cure rates when 250. mg and 500. mg levofloxacin twice daily were used, respectively. These success rates were higher as compared to that of either standard sequential or triple therapies. Other modified sequential therapies did not achieved acceptably high cure rates. Contradictory results emerged from 2 studies assessing the efficacy of a levofloxacin-based sequential regimen as a second-line therapy. Conclusions: Both levofloxacin- and tetracycline-based sequential therapies have been proved to be more effective than standard triple therapies, confirming that the 'sequential' administration of drugs is a successful therapeutic procedure for H. pylori infection. © 2012 Editrice Gastroenterologica Italiana S.r.l.

Modified sequential therapy regimens for Helicobacter pylori eradication: A systematic review / Zullo, A.; De Francesco, V.; Hassan, C.; Ridola, L.; Repici, A.; Bruzzese, V.; Vaira, D.. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 45:1(2013), pp. 18-22. [10.1016/j.dld.2012.08.025]

Modified sequential therapy regimens for Helicobacter pylori eradication: A systematic review

Ridola L.;
2013

Abstract

Background: Different modified sequential therapies have been proposed for Helicobacter pylori eradication. However, the efficacy of these regimens is controversial. Methods: We performed a systematic review of the literature and pooled-data analysis to assess: (a) the efficacy of different modified sequential therapies for H. pylori eradication, (b) the eradication rates achieved by these regimens as compared to either standard triple therapies or standard sequential regimen when available. Results: Overall 21 trials met inclusion criteria. The most used modified sequential therapy was the seven plus seven tetracycline-based regimen which achieved an overall 73.3% eradication rate (6 trials). Such therapy was more effective than the 14-day triple therapy (77.2% vs. 63.6%; 3 trials). The most used five plus five levofloxacin-based sequential therapy achieved a 95.8% and 90% cure rates when 250. mg and 500. mg levofloxacin twice daily were used, respectively. These success rates were higher as compared to that of either standard sequential or triple therapies. Other modified sequential therapies did not achieved acceptably high cure rates. Contradictory results emerged from 2 studies assessing the efficacy of a levofloxacin-based sequential regimen as a second-line therapy. Conclusions: Both levofloxacin- and tetracycline-based sequential therapies have been proved to be more effective than standard triple therapies, confirming that the 'sequential' administration of drugs is a successful therapeutic procedure for H. pylori infection. © 2012 Editrice Gastroenterologica Italiana S.r.l.
2013
H. pylori; Levofloxacin; Modified sequential therapy; Quinolones; Sequential therapy; Tetracycline
01 Pubblicazione su rivista::01a Articolo in rivista
Modified sequential therapy regimens for Helicobacter pylori eradication: A systematic review / Zullo, A.; De Francesco, V.; Hassan, C.; Ridola, L.; Repici, A.; Bruzzese, V.; Vaira, D.. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 45:1(2013), pp. 18-22. [10.1016/j.dld.2012.08.025]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1438980
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 26
social impact